Thomas B. Powles
National Health Service · 913 works · 52,173 citations · h-index 94
Top works
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- EAU Guidelines on Renal Cell Carcinoma: 2014 Update
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial